Clinical studies have demonstrated that Cadonilimab exhibits a favorable safety profile, particularly showing a marked reduction in high-grade irAEs, such as colitis and hypophysitis, compared to conventional CTLA-4 inhibitors (4). Here, CTLA4 is linked to hypophysitis.